By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Senhwa Biosciences 

9191 Towne Centre Drive, Suite 575

San Diego  California  92122  U.S.A.
Phone: 1-858- 552-6808 Fax: 1-858-552-6811



Company News
Senhwa Biosciences CX-4945 Granted Orphan Drug Designation By The US FDA In Cholangiocarcinoma 1/4/2017 7:28:15 AM
Senhwa Biosciences Appoints Lucas S. Chang As General Counsel 12/14/2016 8:22:18 AM
Senhwa Biosciences CX-4945 Phase I Clinical Trial Results Accepted For Presentation At The 2017 ASCO Gastrointestinal Cancers Symposium 12/6/2016 7:25:42 AM
Senhwa Biosciences Files New Patent Applications For Use Of CX-5461 In Combination With PARP Inhibitors, PI3K And Immunotherapeutic Agents 11/15/2016 6:47:04 AM
Senhwa Biosciences Release: FDA Approves Clinical Trial Application (CTA) For Phase I/II Clinical Trial Of CX-5461 In Solid Tumors And Breast Cancers 4/1/2016 6:10:07 AM
Senhwa Biosciences Enters Into Clinical Trial Agreement With CCTG For Phase I/II Study In Triple Negative Breast Cancer 3/9/2016 6:35:35 AM
SU2C Canada - CBCF Breast Cancer Dream Team To Evaluate Senhwa Biosciences's CX-5461 For Breast Cancer 10/1/2015 7:56:55 AM
Senhwa Biosciences and Chaperone Therapeutics Forge $102.7 Million Proteopathies Deal 9/8/2015 9:34:47 AM
Senhwa Biosciences Initiates Phase 1/2 Trial Of CX-4945 In Combination With Gemcitabine And Cisplatin 6/17/2014 10:19:13 AM
Senhwa Biosciences Announces CX-5461 Research Findings To Be Presented At American Association for Cancer Research 3/27/2014 6:39:42 AM